Reduce bounce rates
Read Time:1 Minute, 54 Second

A New Drug Compound Shows Promise for Schizophrenia

For people with schizophrenia, treatment is an ongoing, life-long process of antipsychotic medications and psychotherapy. Medications are key to controlling episodes, but most have serious enough side effects—including uncontrolled muscle movements, gaining weight and drowsiness—that people skip doses or decide not to take them.

In a study published Dec. 14 in the Lancet, researchers report on a promising new treatment for the psychiatric disorder that could give patients better options. KarXT, developed by biotech company Karuna Therapeutics, targets a different brain chemical than most existing schizophrenia treatments and appears to have fewer side effects.

The study involved 252 people who were hospitalized with schizophrenia and randomly assigned to receive two capsules of KarXT, or a placebo, per day for five weeks. Those taking the drug showed fewer extremes of positive and negative symptoms associated with acute psychosis than those on placebo. Both groups has similar rates of side effects, including constipation, diarrhea, reflux and hypertension.

“This represents a new option, and a new approach in an area where there is still substantial need for advances in treatments,” says Andrew Miller, chief operating officer of Karuna.

Unlike existing schizophrenia treatments, which target the brain chemical dopamine, KarXT targets the muscarinic neurotransmitter system in the brain, which is involved in cognition. The muscarinic receptors on brain cells bind with the brain chemical acetylcholine, which is the target of certain cognition-related treatments for Alzheimer’s disease. In studies that Karuna conducted in these patients, its scientists found that patients with Alzheimer’s-related psychoses seemed to benefit as well. “By targeting a completely different neurotransmitter system, through completely different receptors, clinical data uncovered novel benefits without the problematic side effects of existing treatments,” he says.

But because muscarinic receptors are found widely throughout the body, creating a drug that targets them was challenging, since it would trigger serious side effects. To solve the problem, Karuna scientists combined its compound with another that blocked the drug from acting outside of the brain. “That enabled the development of KarXT,” Miller says.

Karuna has submitted the results of this trial as part of it request to the U.S. Food and Drug Administration for approval; the agency will make a decision by Sept. 2024.

Happy
Happy
0 %
Sad
Sad
0 %
Excited
Excited
0 %
Sleepy
Sleepy
0 %
Angry
Angry
0 %
Surprise
Surprise
0 %

Average Rating

5 Star
0%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%

2 thoughts on “A New Drug Compound Shows Promise for Schizophrenia

  1. Cuando tenga dudas sobre las actividades de sus hijos o la seguridad de sus padres, puede piratear sus teléfonos Android desde su computadora o dispositivo móvil para garantizar su seguridad. Nadie puede monitorear las 24 horas del día, pero existe un software espía profesional que puede monitorear en secreto las actividades de los teléfonos Android sin avisarles.

  2. Instalación simple y descarga gratuita, no se requieren conocimientos técnicos y no se requiere raíz.Grabacion de llamadas, Grabacion de entorno, Ubicaciones GPS, Mensajes Whatsapp y Facebook, Mensajes SMS y muchas características mas.

Leave a Reply

Your email address will not be published. Required fields are marked *

highlights of 2023 Previous post Beyond COVID-19 : Long-Term Effects of Viral Infections
6 Myths About IBD Next post 6 Myths About IBD, Debunked:Unraveling the Realities of Inflammatory Bowel Disease (IBD)